CLSA Adjusts 3SBIO Price Target Downward to HK$30.4, Keeps Outperform Rating

Stock News

Yesterday

According to a research report released by CLSA, the first-half performance of 3SBIO (01530) has benefited from milestone revenue related to its 707 program and robust growth in its CDMO business, which together offset the impact of weaker sales from core products. Although near-term revenue growth remains subdued, the launch of a new product cycle and further progress in the global development of the 707 program are expected to support medium-term growth. The firm has maintained its "Outperform" rating while trimming the target price to HK$30.4 from HK$32.6. The company currently holds over RMB 18.6 billion in cash; excluding this cash, the stock is trading at a forward price-to-earnings ratio of 7.4 times for the next year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/news/1111788244"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111788244\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111788244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 12:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111788244","market":"sg","top_or_hot":-1,"title":"CLSA Adjusts 3SBIO Price Target Downward to HK$30.4, Keeps Outperform Rating","media":"Stock News","content":"<p>According to a research report released by CLSA, the first-half performance of <b>3SBIO</b> (01530) has benefited from milestone revenue related to its 707 program and robust growth in its CDMO business, which together offset the impact of weaker sales from core products. Although near-term revenue growth remains subdued, the launch of a new product cycle and further progress in the global development of the 707 program are expected to support medium-term growth. The firm has maintained its \"Outperform\" rating while trimming the target price to HK$30.4 from HK$32.6. The company currently holds over RMB 18.6 billion in cash; excluding this cash, the stock is trading at a forward price-to-earnings ratio of 7.4 times for the next year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLSA Adjusts 3SBIO Price Target Downward to HK$30.4, Keeps Outperform Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLSA Adjusts 3SBIO Price Target Downward to HK$30.4, Keeps Outperform Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-31 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to a research report released by CLSA, the first-half performance of <b>3SBIO</b> (01530) has benefited from milestone revenue related to its 707 program and robust growth in its CDMO business, which together offset the impact of weaker sales from core products. Although near-term revenue growth remains subdued, the launch of a new product cycle and further progress in the global development of the 707 program are expected to support medium-term growth. The firm has maintained its \"Outperform\" rating while trimming the target price to HK$30.4 from HK$32.6. The company currently holds over RMB 18.6 billion in cash; excluding this cash, the stock is trading at a forward price-to-earnings ratio of 7.4 times for the next year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1111788244","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111788244","pubTimestamp":1788148823,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to a research report released by CLSA, the first-half performance of 3SBIO (01530) has benefited from milestone revenue related to its 707 program and robust growth in its CDMO business,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1593":"医美概念股","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","EWH":"香港ETF-iShares MSCI","BK1583":"高瓴概念","01530":"三生制药","BK1161":"生物科技"},"translate_title":"里昂证券将三生制药目标价下调至30.4港元，维持跑赢大盘评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1,"EWH":1},"content_text":"According to a research report released by CLSA, the first-half performance of 3SBIO (01530) has benefited from milestone revenue related to its 707 program and robust growth in its CDMO business, which together offset the impact of weaker sales from core products. Although near-term revenue growth remains subdued, the launch of a new product cycle and further progress in the global development of the 707 program are expected to support medium-term growth. The firm has maintained its \"Outperform\" rating while trimming the target price to HK$30.4 from HK$32.6. The company currently holds over RMB 18.6 billion in cash; excluding this cash, the stock is trading at a forward price-to-earnings ratio of 7.4 times for the next year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}